Valuation
- Market cap
- 8,256,000
- Revenue TTM
- $0
- Net income TTM
- $-18,650,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 148,700
- Avg volume
- 235,914
- Day's range
- $1.10 – $1.24
- Shares out
- 6,658,000
- Stochastic %K
- 37%
- Beta
- 1.72
- Analysts
- Sell
- Price target
- $6.00
Company profile
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment...
Show more
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 281 671 5150
- Website
- https://fibrobiologics.com
- Address
- 455 East Medical Center Boulevard, Suite 300, Houston, United States
Latest news
No headlines yet.
